Restoring this week’s @PGAChampionship venue required lots of two things: photographic research, and tree removal 🌲🚜
Here’s Gil Hanse on why the latter piece was essential to revive Donald Ross’ vision for Aronimink ⛳️
@SmylieKaufman10 | @charliehulme | @SportsGridTV
COMEBACK COMPLETE 🏆
5,000+ DAYS SINCE HIS LAST PROFESSIONAL GOLF WIN. A 12-YEAR HIATUS FROM THE SPORT. CUT FROM LIV AFTER 2 SEASONS AND HAD TO EARN HIS SPOT BACK.
ANTHONY KIM WITH ONE OF THE ALL-TIME HEATERS YOU WILL EVER SEE.
SO BACK.
The California Golf Club of San Francisco, better known as Cal Club, has established a reputation as one of the best maintained golf courses in the Bay Area.
In our latest episode of All Grass Is Local, we take you behind the scenes with Superintendent Javier Campos and his team to find out how they maintain a uniquely firm-and-fast fescue surface in foggy South San Francisco.
(Presented by @ToroGolf)
Sputtering? Zero chances. I’m empathetic to the personal stories, but don’t think these anecdotes reflect the reality on the ground. I’m feeling more positive now than in years.
Biotech is a cyclic business. We had a bubble of overbuilding, overhiring, and overfunding, followed by retrenchment for a couple years. We’re in a healthier place now. We still have 2x more VC funding in biotech than a decade ago. IPOs dried up but are coming back. XBi is up significantly. And we’re now entering an expansion part of the cycle.
Lab vacancy rates have more to do with the massive lab build out, creating a huge glut of supply, than a long term pullback in biotech relative to pre-pandemic bubble lab usage. Ridiculous rents in the face of demand drove overbuilding of labs, which take years to come online - thus the glut today.
I’m an optimist on the sector and on Kendall specifically. Interest rates, M&A, catalytic data, sector rotation into biopharma, and fading macro risks all create tailwinds. Boston remains the global epicenter of biopharma R&D. In the US, I’m concerned about further FDA chaos, but am hopeful we can manage thru that…
China is both threat and opportunity - bringing new drugs to patients globally is a good thing. And raising the competitive pressure to do things faster and cheaper in the US is healthy. Appropriate regulatory changes need to happen, and I think will over time.
But fundamentally the Boston biotech cluster, and the western biotech sector more broadly, are poised for a renewed positive run over the next few years.
The reports of our death, or sputtering, are greatly exaggerated…
@cirsay is a true leader and understands her organization better than any other owner in football. @woodyjohnson4 just got worked, maybe u should ask her for cliff notes.